Vaccines News and Research RSS Feed - Vaccines News and Research

Researchers develop mouse model to improve basic research on Ebola treatments, vaccines

Researchers develop mouse model to improve basic research on Ebola treatments, vaccines

Researchers at the University of North Carolina at Chapel Hill and colleagues have developed the first genetic strain of mice that can be infected with Ebola and display symptoms similar to those that humans experience. [More]
University of Adelaide-led project develops new test to eradicate H5N1 bird flu

University of Adelaide-led project develops new test to eradicate H5N1 bird flu

A University of Adelaide-led project has developed a new test that can distinguish between birds that have been vaccinated against the H5N1 strain of avian influenza virus or "bird flu" with those that have been naturally infected. [More]
Profectus BioSciences gets funding to develop VesiculoVax Zaire-Ebola virus vaccine

Profectus BioSciences gets funding to develop VesiculoVax Zaire-Ebola virus vaccine

Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases, announced today that the Department of Defense through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program, a subordinate command of the Joint Program Executive Office for Chemical and Biological Defense, Edgewood, MD, has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine. [More]
Special issue of Technology and Innovation includes articles from Patents for Humanity winners

Special issue of Technology and Innovation includes articles from Patents for Humanity winners

The current special issue of Technology and Innovation, is devoted to patents that benefit people around the world who live with limited resources, in challenging environments, and are in need of better access to basic needs and improved standards of living, health and infrastructure. [More]
NCI supports further clinical development of next-generation HPV vaccine

NCI supports further clinical development of next-generation HPV vaccine

The National Cancer Institute in the USA is supporting the new vaccine developed at the MedUni Vienna against the human papillomavirus (HPV) with at least US$ 3.5 million. This is a major success for the developers and means that the foundations can now be laid for the clinical trials needed for licensing as a vaccine. [More]
Research breakthroughs may pave way for new drugs to fight against parasitic worm infections

Research breakthroughs may pave way for new drugs to fight against parasitic worm infections

Recent breakthroughs may pave the way for vaccines and new drugs for those infected by parasitic helminths. These flatworms, including tapeworms that cause hydatid diseases and neurocysticercosis, liver flukes, and blood flukes (schistosomes), infect more than 300 million people and cause approximately four million disability-adjusted life years lost due to chronic illness and death each year. [More]
ETEC vaccine candidate provides significant protection against bacterial diarrhea

ETEC vaccine candidate provides significant protection against bacterial diarrhea

New results from a safety and immunogenicity study, which included a challenge phase to test efficacy, indicate that a live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine candidate, given in combination with a novel adjuvant, provided significant protection against disease. [More]
Imaxio awarded ANR funding to improve efficacy of vaccines for seasonal influenza

Imaxio awarded ANR funding to improve efficacy of vaccines for seasonal influenza

Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has been awarded funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project 'leveraging On t-cell immune resPonse To Improve influenza VACcines'. [More]
Rewriting the family history of Ebola

Rewriting the family history of Ebola

The research shows that filoviruses — a family to which Ebola and its similarly lethal relative, Marburg, belong — are at least 16-23 million years old. [More]
WHO holds meeting to discuss on how to fast track testing, deployment of Ebola vaccines

WHO holds meeting to discuss on how to fast track testing, deployment of Ebola vaccines

WHO convened a meeting with high-ranking government representatives from Ebola-affected countries and development partners, civil society, regulatory agencies, vaccine manufacturers and funding agencies yesterday to discuss and agree on how to fast track testing and deployment of vaccines in sufficient numbers to impact the Ebola epidemic. [More]
Helping children understand Ebola

Helping children understand Ebola

It dominates the headlines and is striking fear and panic in many communities around the world, Ebola. The constant barrage of information and so much unknown can be especially difficult for children, making it all the more important for parents to help their kids feel safe and to have a dialogue with them at the appropriate developmental level. [More]
ADI develops ELISA test kits for detection of Ebola viral protein antibodies

ADI develops ELISA test kits for detection of Ebola viral protein antibodies

San Antonio, Texas-based Biotech Company Alpha Diagnostic Int'l has developed and released several convenient, rapid, and sensitive ELISA test kits for the detection of major Ebola viral protein antibodies (Glycoprotein, GP; Nucleoprotein, NP, and Viral Protein 40 or VP40). [More]
Flu vaccines have protective effect against heart disease

Flu vaccines have protective effect against heart disease

Flu vaccines are known to have a protective effect against heart disease, reducing the risk of a heart attack. For the first time, this research, published in Vaccine, reveals the molecular mechanism that underpins this phenomenon. The scientists behind the study say it could be harnessed to prevent heart disease directly. [More]
Two IOM members honored for outstanding service

Two IOM members honored for outstanding service

The Institute of Medicine honored members Dan G. Blazer and Richard B. Johnston Jr. for their outstanding service during the IOM's 44th annual meeting in Washington, D.C. [More]
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen Research & Development, LLC today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc. [More]
Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. [More]
Ebola Virus and Public Health: A special feature by Disaster Medicine and Public Health

Ebola Virus and Public Health: A special feature by Disaster Medicine and Public Health

Accurate knowledge regarding Ebola is critical and pertinent for practicing physicians and clinicians given the current risk of hazardous global outbreak and epidemic. [More]
TSRI scientists identify long-sought activating molecules for subset of immune system cells

TSRI scientists identify long-sought activating molecules for subset of immune system cells

Scientists at The Scripps Research Institute (TSRI) have identified the long-sought activating molecules for a rare but crucial subset of immune system cells that help rally other white blood cells to fight infection. [More]
Scientists develop promising vaccination strategy to counteract RSV infection

Scientists develop promising vaccination strategy to counteract RSV infection

Respiratory Syncytial Virus causes severe respiratory tract infections and worldwide claims the lives of 160,000 children each year. Scientists at VIB and Ghent University have succeeded in developing a promising vaccination strategy to counteract this common virus infection. [More]
NIAID announces license agreement to develop dual-purpose candidate vaccines for rabies, Ebola

NIAID announces license agreement to develop dual-purpose candidate vaccines for rabies, Ebola

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced a new license agreement aimed at advancing dual-purpose candidate vaccines to protect against rabies and Ebola viruses. [More]